Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164244 | 0.81 | HTT (0.68) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL17516462 | 0.79 | HTR2C (0.65) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL30945075 | 0.79 | HTR2C (0.65) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL4245389 | 0.79 | HTR2C (0.65) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL4192433 | 0.79 | HTR2C (0.65) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL12789880 | 0.79 | MEN1 (0.66) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL13640916 | 0.75 | HTR2C (0.72) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL2048915 | 0.75 | AKT2 (0.70) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL13431592 | 0.74 | SMN1; SMN2 (0.67) | STAT3SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL12789895 | 0.74 | MEN1 (0.71) | STAT3SMN1; SMN2HTTMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035437-A1 | IgY ANTIBODIES TARGETING MONKEYPOX VIRUS AND METHODS OF USE THEREOF | MARC MEDICAL SERVICES AND SCIENT RESEARCH (EG) | 2026-02-05 | — | — | US | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-2320904-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035437-A1 | IgY ANTIBODIES TARGETING MONKEYPOX VIRUS AND METHODS OF USE THEREOF | IGSF11, MLX, IGLV6-57 | STAT3 3537/4885SMN1; SMN2 2370/4885HTT 3726/4885 |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | STAT3 3958/4885SMN1; SMN2 4740/4885HTT 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.